R
Richard A. Adegbola
Researcher at GlaxoSmithKline
Publications - 203
Citations - 17345
Richard A. Adegbola is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Population & Tuberculosis. The author has an hindex of 63, co-authored 192 publications receiving 15922 citations. Previous affiliations of Richard A. Adegbola include Medical Research Council & University of London.
Papers
More filters
Journal ArticleDOI
Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.
Karen L. Kotloff,James P. Nataro,William C. Blackwelder,Dilruba Nasrin,Tamer H. Farag,Sandra Panchalingam,Yukun Wu,Samba O. Sow,Dipika Sur,Robert F. Breiman,Abu Syed Golam Faruque,Anita K. M. Zaidi,Debasish Saha,Pedro L. Alonso,Boubou Tamboura,Doh Sanogo,Uma Onwuchekwa,Byomkesh Manna,Thandavarayan Ramamurthy,Suman Kanungo,John B. Ochieng,Richard Omore,Joseph Oundo,Anowar Hossain,Sumon Kumar Das,Shahnawaz Ahmed,Shahida Qureshi,Farheen Quadri,Richard A. Adegbola,Richard A. Adegbola,Martin Antonio,M. Jahangir Hossain,Adebayo Akinsola,Inacio Mandomando,Tacilta Nhampossa,Sozinho Acácio,Kousick Biswas,Ciara E. O’Reilly,Eric D. Mintz,Lynette Y. Berkeley,Lynette Y. Berkeley,Khitam Muhsen,Halvor Sommerfelt,Halvor Sommerfelt,Roy M. Robins-Browne,Myron M. Levine +45 more
TL;DR: Interventions targeting five pathogens can substantially reduce the burden of moderate-to-severe diarrhoea and suggest new methods and accelerated implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent disease and improve outcomes.
Journal ArticleDOI
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
Felicity T. Cutts,Syed M. A. Zaman,Godwin Enwere,Shabbar Jaffar,Orin S. Levine,Orin S. Levine,J. B. Okoko,Claire Oluwalana,Adeola Vaughan,Steven Obaro,Amanda Leach,Keith P. W. J. McAdam,Ekow Biney,Mark Saaka,U. Onwuchekwa,Fred G. Yallop,Nathaniel F. Pierce,Brian Greenwood,Richard A. Adegbola +18 more
TL;DR: Pneumococcal conjugate vaccine has high efficacy against radiological pneumonia and invasive pneumococcal disease, and can substantially reduce admissions and improve child survival in this rural African setting.
Journal ArticleDOI
Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants
Kim Mulholland,Stephen Hilton,Richard A. Adegbola,Stanley Usen,Anslem Oparaugo,Charles Omosigho,Martin W. Weber,Ayo Palmer,G. Schneider,Kebba Jobe,George Lahai,Shabbar Jaffar,Ousman Secka,Kimi Lin,Chantal Ethevenaux,Brian Greenwood +15 more
TL;DR: The reduction in the overall incidence of radiologically defined pneumonia in PRP-T vaccinees suggests that about 20% of episodes of pneumonia in young Gambian children are due to Hib, which should substantially reduce childhood mortality due to pneumonia and meningitis.
Journal ArticleDOI
Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum
Natalie J. Garton,Simon J. Waddell,Anna L Sherratt,Su-Min Lee,Rebecca J. Smith,Claire E. Senner,Jason Hinds,Kumar Rajakumar,Richard A. Adegbola,Gurdyal S. Besra,Philip D. Butcher,Michael R. Barer +11 more
TL;DR: Transcript analyses refute the hypothesis that these cells predominate in sputum and reinforce the results of the lipid body analyses by revealing transcriptional signatures that can be clearly attributed to slowly replicating or nonreplicating mycobacteria.
Journal ArticleDOI
Identifying Recent Adaptations in Large-Scale Genomic Data
Shamai A. Grossman,Shamai A. Grossman,Shamai A. Grossman,Kristian G. Andersen,Kristian G. Andersen,Ilya Shlyakhter,Ilya Shlyakhter,Shervin Tabrizi,Shervin Tabrizi,Sarah M. Winnicki,Sarah M. Winnicki,Angela Yen,Angela Yen,Daniel J. Park,Daniel J. Park,Dustin Griesemer,Elinor K. Karlsson,Elinor K. Karlsson,Sunny H. Wong,Moran N. Cabili,Moran N. Cabili,Richard A. Adegbola,Rameshwar N. K. Bamezai,Adrian V. S. Hill,Fredrik O. Vannberg,John L. Rinn,John L. Rinn,John L. Rinn,Eric S. Lander,Eric S. Lander,Eric S. Lander,Stephen F. Schaffner,Pardis C. Sabeti,Pardis C. Sabeti +33 more
TL;DR: One candidate nonsynonymous variant in Toll-like receptor 5 (TLR5) is experimentally characterized and it is shown that it leads to altered NF-κB signaling in response to bacterial flagellin.